AR022462A1 - USE OF AN AGENT THAT DECREASES CHOLESTEROL - Google Patents

USE OF AN AGENT THAT DECREASES CHOLESTEROL

Info

Publication number
AR022462A1
AR022462A1 ARP000100408A ARP000100408A AR022462A1 AR 022462 A1 AR022462 A1 AR 022462A1 AR P000100408 A ARP000100408 A AR P000100408A AR P000100408 A ARP000100408 A AR P000100408A AR 022462 A1 AR022462 A1 AR 022462A1
Authority
AR
Argentina
Prior art keywords
agent
dosages
oral
decreases cholesterol
compound
Prior art date
Application number
ARP000100408A
Other languages
Spanish (es)
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR022462(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902590.0A external-priority patent/GB9902590D0/en
Priority claimed from GBGB9921062.7A external-priority patent/GB9921062D0/en
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of AR022462A1 publication Critical patent/AR022462A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La presente concierne el uso de dosificaciones orales o rangos de dosificacion oral del compuesto ácido (E)-7-[4-(4-florofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il]-(3R,5S)-3,5-dihidroxihept-6-enoico, o de una sal del mismo aceptable para uso farmacéutico, para alterar beneficiosamentelos niveles o las relaciones de lípidos en un paciente humano que lo necesita, así como composiciones farmacéuticas de dicho compuesto o sales adaptadas parala administracion oral que comprendentales dosificaciones, y métodos para su preparacion.This concerns the use of oral dosages or oral dosage ranges of the acid compound (E) -7- [4- (4-florophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] - (3R, 5S) -3,5-dihydroxyhept-6-enoic, or a salt thereof acceptable for pharmaceutical use, to beneficially alter the levels or lipid ratios in a human patient in need thereof, as well as pharmaceutical compositions of said compound or salts adapted for oral administration comprising dosages, and methods for their preparation.

ARP000100408A 1999-02-06 2000-01-31 USE OF AN AGENT THAT DECREASES CHOLESTEROL AR022462A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9902590.0A GB9902590D0 (en) 1999-02-06 1999-02-06 Use of cholesterol-lowering agent
GBGB9921062.7A GB9921062D0 (en) 1999-09-08 1999-09-08 Use of cholestrol-lowering agent

Publications (1)

Publication Number Publication Date
AR022462A1 true AR022462A1 (en) 2002-09-04

Family

ID=26315084

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100408A AR022462A1 (en) 1999-02-06 2000-01-31 USE OF AN AGENT THAT DECREASES CHOLESTEROL

Country Status (22)

Country Link
EP (1) EP1150679A1 (en)
JP (2) JP2002536333A (en)
KR (1) KR100699287B1 (en)
CN (1) CN1347320A (en)
AR (1) AR022462A1 (en)
AU (1) AU769897B2 (en)
BR (1) BR0007991A (en)
CA (1) CA2358641A1 (en)
CZ (1) CZ20012631A3 (en)
EE (1) EE04659B1 (en)
HK (1) HK1040924A1 (en)
HU (1) HUP0105019A3 (en)
ID (1) ID30131A (en)
IL (1) IL144662A0 (en)
IS (1) IS5996A (en)
MY (1) MY136382A (en)
NO (1) NO319827B1 (en)
NZ (1) NZ512681A (en)
PL (1) PL349137A1 (en)
SK (1) SK11112001A3 (en)
TR (1) TR200102236T2 (en)
WO (1) WO2000045819A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
SE0103509D0 (en) * 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre-demented states
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2007142581A1 (en) * 2006-06-07 2007-12-13 Astrazeneca Ab Combination product for the treatment or prevention of dyslipidaemia
JP2010530417A (en) * 2007-06-20 2010-09-09 メルク・シャープ・エンド・ドーム・コーポレイション CETP inhibitors derived from benzoxazole arylamides
EP2170058B1 (en) 2007-06-20 2013-07-03 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
AU2008266957A1 (en) * 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. CETP inhibitors derived from benzoxazole arylamides
EP2216095A1 (en) * 2009-01-27 2010-08-11 Koninklijke Philips Electronics N.V. Microfluidic device for full blood count

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260446A (en) * 1989-12-22 1993-11-09 Basf Aktiengesellschaft Aminothiazoles
JP2648897B2 (en) * 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives

Also Published As

Publication number Publication date
PL349137A1 (en) 2002-07-01
EP1150679A1 (en) 2001-11-07
BR0007991A (en) 2001-11-06
EE200100404A (en) 2002-10-15
EE04659B1 (en) 2006-08-15
TR200102236T2 (en) 2001-12-21
JP2002536333A (en) 2002-10-29
KR20010089631A (en) 2001-10-06
NO319827B1 (en) 2005-09-19
ID30131A (en) 2001-11-08
NO20013810D0 (en) 2001-08-03
IL144662A0 (en) 2002-05-23
HUP0105019A2 (en) 2002-05-29
SK11112001A3 (en) 2002-02-05
CZ20012631A3 (en) 2001-10-17
MY136382A (en) 2008-09-30
CN1347320A (en) 2002-05-01
HUP0105019A3 (en) 2003-02-28
KR100699287B1 (en) 2007-03-26
WO2000045819A1 (en) 2000-08-10
IS5996A (en) 2001-07-10
NO20013810L (en) 2001-10-03
NZ512681A (en) 2003-12-19
AU769897B2 (en) 2004-02-05
CA2358641A1 (en) 2000-08-10
AU2305100A (en) 2000-08-25
HK1040924A1 (en) 2002-06-28
JP2011137023A (en) 2011-07-14

Similar Documents

Publication Publication Date Title
ES2171123B1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A PYRIMIDIN-5-IL- (3R, 5S) -3,5-DIHYDROXIHEPT-6-EMOIC ACID OR A SALT OF THE SAME AND AN INORGANIC SALT IN WHICH THE CATION IS MULTIVALLY.
AR110010A2 (en) PHARMACEUTICAL COMPOSITION FORMULATED IN A SINGLE DOSE FORM OF 2- [6- (3-AMINO-PIPERIDIN-1-IL) -3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-ILLAMBLE ] -4-FLUORO-BENZONITRILO
AR037629A1 (en) PHARMACEUTICAL FORMULATIONS THAT INCLUDE A PLATINUM DERIVATIVE
NO20053817L (en) Preparations and Methods for Antiviral Combination Therapy.
AR031766A1 (en) THERAPY
ES2156028T3 (en) Compositions containing tetrahydrolipstatin
CY1109756T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING Crystalline Salts 7- [4- (4-Fluorophenyl) -6-Isopropyl-2- [Methyl (Methylsulfonyl) -5-5-yl] -3-5-amino-3-yl] -5-y -NIGHT ACID
CY1112376T1 (en) 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists
BR0114799A (en) Cyanophenoxy carboxylic acid compounds and compositions for releasing active agents
AR037592A1 (en) PHARMACEUTICAL FORMULATIONS OF 5,7,14-TRIAZATETRACICLO (10.3.1.02,11.04,9) -HEXADECA-2 (11), 3,5,7,9-PENTAENO
JP2006508953A5 (en)
NO20043871L (en) Controlled release drug formulations containing a carrier peptide
AR065731A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 2- [6- (3-AMINO-PIPENIDIN-1-IL) -3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PRIMIDIN-1-IL METHYL] -4-FLUORO -BENZONITRILE. USE. TREATMENT METHOD, WEEKLY ADMINISTRATION OF DIPEPTIDILPEPTIDASA INHIBITORS.
PT1207756E (en) USE OF ESPINOSADE OR A FORMULATION THAT INCLUDES ESPINOSADE
NO20024646D0 (en) Combination therapies with vasculature-damaging activity
DK1383752T3 (en) Deuterated 3-piperidinopropiophenones as well as drugs containing these compounds
AR022462A1 (en) USE OF AN AGENT THAT DECREASES CHOLESTEROL
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
BRPI0620629B8 (en) pharmaceutical composition, process for preparing a pharmaceutical composition and its use
AR055614A1 (en) COMBINATION OF PHARMACEUTICAL SUBSTANCES FOR THE TREATMENT OF RESPIRATORY DISEASES
CY1108684T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ASCORBIC ACID FOR THE FUNCTIONAL TREATMENT AND FUNCTIONAL REFERENCES
AR087240A2 (en) PHARMACEUTICAL COMPOSITIONS THAT HAVE EPINASTINE AND PSEUDOEFEDRINE
ATE460934T1 (en) PHARMACEUTICAL PREPARATIONS OF CIPROFLOXACIN
BR0212744A (en) Cisplatin formulations of reduced toxicity and methods for their use
DE602004014964D1 (en) PHARMACEUTICAL COMPOSITION WITH A CATIONIC AGENT

Legal Events

Date Code Title Description
FB Suspension of granting procedure